Transcatheter Intra-arterial Limb Infusion of Cisplatin for Extremity Osteosarcoma
Status:
Completed
Trial end date:
2019-04-08
Target enrollment:
Participant gender:
Summary
Although there seems to be no benefit from improving the histologic response rate or
long-term survival of intra-arterial infusion of cisplatin for localized osteosarcoma of
extremities with IOR/OS-3, IOR/OS-5, and COSS 86 protocols, such a treatment strategy is
still believed to potentially increase the tumoricidal effect with an increase in higher
local concentrations of the infused agents combined with longer tissue exposure time.
Besides, the relationship of chemotherapy-induced necrosis and surgical margins is still the
main concern for localized osteosarcoma patients to achieve long-term survival. The
investigators intend to analyze the gain and loss from transcatheter intra-arterial limb
infusion of cisplatin for extremity osteosarcoma in the past six years.